Liminatus Pharma, Inc. (LIMN): R&D Expense

Annual figures by period end, from SEC filings.

$2.69M

Year ended 2024-12-31

Period ended	R&D Expense	Change YoY	Source filing
2024-12-31	$2.69M	n/a	2026-03-31, From 2024-01-01